Recent News

• 02.26.2025 - Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines
• 02.21.2025 - Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market
• 02.18.2025 - Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD)
• 01.28.2025 - Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as a Treatment for Avian Influenza (Bird Flu) and Other Viruses
• 01.07.2025 - Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging)
• 12.23.2024 - Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson’s Disease
• 12.12.2024 - Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price
• 12.03.2024 - Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1

Recent Filings

• 02.25.2025 - 8-K Current report
• 02.20.2025 - 8-K Current report
• 02.18.2025 - 8-K Current report
• 02.14.2025 - S-3 Registration statement under Securities Act of 1933
• 02.04.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.04.2025 - 5 Annual statement of changes in beneficial ownership of securities
• 01.28.2025 - 8-K Current report
• 01.07.2025 - 8-K Current report
• 12.23.2024 - 8-K Current report
• 12.20.2024 - 8-K Current report